Clinical disorders of bone resorption.

Clinical disorders of bone resorption.

Clinical disorders in which bone resorption is increased are very common and include Paget's disease of bone, osteoporosis, and the bone changes secondary to cancer, such as occur in myeloma and metastases from breast cancer. Clinical disorders of reduced bone resorption are less common and oft...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Russell, G, Mueller, G, Shipman, C, Croucher, P
Natura:	Journal article
Lingua:	English
Pubblicazione:	2001

Documenti analoghi

Dkk1 modulates osteoclastogenesis and bone resorption: Implications for myeloma bone disease.
di: Oyajobi, B, et al.
Pubblicazione: (2005)

LIGHT (TNFSF14), a novel mediator of normal and pathological bone resorption.
di: Edwards, J, et al.
Pubblicazione: (2004)

Bone resorption /
di: Bronner, Felix., et al.
Pubblicazione: (2005)

Osteoprotegerin and the development of myeloma bone disease
di: Croucher, P, et al.
Pubblicazione: (2004)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
di: Locklin, R, et al.
Pubblicazione: (2005)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
di: Shipman, C, et al.
Pubblicazione: (2002)

LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis.
di: Edwards, J, et al.
Pubblicazione: (2006)

Cellular biology of bone resorption.
di: Zaidi, M, et al.
Pubblicazione: (1993)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
di: De Leenheer, E, et al.
Pubblicazione: (2004)

Bone Resorption Assay
di: Carina Scholtysek, et al.
Pubblicazione: (2014-07-01)

Light, a TNF-superfamily member, induces osteoclast formation in vitro; A novel mediator of bone resorption?
di: Edwards, JR, et al.
Pubblicazione: (2004)

Bishosphonates inhibit bone resorption in multicentric reticulohistiocytosis
di: Adamopoulos, I, et al.
Pubblicazione: (2006)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
di: Croucher, P, et al.
Pubblicazione: (2003)

Malignant melanoma and bone resorption.
di: Lau, Y, et al.
Pubblicazione: (2006)

Mechanisms of Bone Resorption in Periodontitis
di: Stefan A. Hienz, et al.
Pubblicazione: (2015-01-01)

Roles of hyaluronan in bone resorption
di: Prince Charles W
Pubblicazione: (2004-04-01)

AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption
di: Sun J, et al.
Pubblicazione: (2023-04-01)

Biochemical Markers of Bone Resorption Compared with Estimates of Bone Resorption from Radiotracer Kinetic Studies in Osteoporosis
di: Eastell, R, et al.
Pubblicazione: (1997)

Polymorphonuclear Neutrophils in Osteomyelitis: Link to Osteoclast Generation and Bone Resorption
di: M.M. Gaida, et al.
Pubblicazione: (2012-09-01)

Effect of smoking on alveolar bone resorption
di: Računica Jelena, et al.
Pubblicazione: (2008-01-01)

PPARG Post-translational Modifications Regulate Bone Formation and Bone Resorption
di: L.A. Stechschulte, et al.
Pubblicazione: (2016-08-01)

Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis.
di: Adamopoulos, I, et al.
Pubblicazione: (2006)

Real-time analysis of osteoclast resorption and fusion dynamics in response to bone resorption inhibitors
di: Preety Panwar, et al.
Pubblicazione: (2024-03-01)

Low-dose doxycycline prevents inflammatory bone resorption in rats
di: M.M. Bezerra, et al.
Pubblicazione: (2002-05-01)

Beyond resorption: osteoclasts as drivers of bone formation
di: Qianfeng Xiang, et al.
Pubblicazione: (2024-10-01)

Overview: Inhibitors of bone resorption and implications for therapy
di: Zaidi, M, et al.
Pubblicazione: (1992)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
di: Shipman, C, et al.
Pubblicazione: (2003)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
di: Shipman, C, et al.
Pubblicazione: (2002)

Interleukin-32, a novel inhibitor of bone resorption in vitro?
di: Mabilleau, G, et al.
Pubblicazione: (2009)

Diagnostic informativeness of markers of bone-tissue metabolism and bone resorption in cows with osteodystrophy
di: L. G. Slivinska, et al.
Pubblicazione: (2023-07-01)

Zika virus infects human osteoclasts and blocks differentiation and bone resorption
di: Noreen Mumtaz, et al.
Pubblicazione: (2022-12-01)

Radio-opaque agents in bone cement increase bone resorption.
di: Sabokbar, A, et al.
Pubblicazione: (1997)

Cellular mechanisms of bone resorption in breast carcinoma.
di: Hunt, N, et al.
Pubblicazione: (2001)

Determination of resorption surface areas of bone sample
di: Margasanti Wijaya.
Pubblicazione: (2009)

Human osteoclast ontogeny and pathological bone resorption.
di: Athanasou, N, et al.
Pubblicazione: (1999)

Stress analysis of femoral hip with bone resorption
di: Shuib, Solehuddin, et al.
Pubblicazione: (2013)

Stress analysis of femoral bone resorption with implant
di: Shuib, Solehuddin, et al.
Pubblicazione: (2013)

Osteoclast biology in bone resorption: a review
di: Chao Fu, et al.
Pubblicazione: (2020-09-01)

Roles of Wnt signaling in bone formation and resorption
di: Yasuhiro Kobayashi, et al.
Pubblicazione: (2008-07-01)

Bone resorption: an actor of dental and periodontal development?
di: Andrea eGama, et al.
Pubblicazione: (2015-11-01)